2025年第三季度,江苏创新药生态继续展现韧性与分层活力。据统计,Q3至少有16家江苏创新药公司获融资,已披露金额合计超25亿元。从轮次结构看,A轮及以前早期融资占比超六成,持续体现出苏州-南京为核心的“早期密集孵化+多赛道并进”的产业特征。从城市分布看,项目集中于苏州(11家)与南京(4家)。从方向上看,小分子药物仍是研发焦点,细胞与基因疗法(CGT)、核酸、抗体、蛋白类并行推进;肿瘤、中枢神经...
Source Link2025年第三季度,江苏创新药生态继续展现韧性与分层活力。据统计,Q3至少有16家江苏创新药公司获融资,已披露金额合计超25亿元。从轮次结构看,A轮及以前早期融资占比超六成,持续体现出苏州-南京为核心的“早期密集孵化+多赛道并进”的产业特征。从城市分布看,项目集中于苏州(11家)与南京(4家)。从方向上看,小分子药物仍是研发焦点,细胞与基因疗法(CGT)、核酸、抗体、蛋白类并行推进;肿瘤、中枢神经...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.